Key points are not available for this paper at this time.
Design
Editorial
Answers are grounded in this paper and cite their sources.
Discusses the historical context of the first clinical trial of captopril for the treatment of hypertension.
RENIN INHIBITORSIN the May 4, 1978, issue of the Journal, Gavras et al. reported the first clinical trial of a new agent that promised a different approach to the treatment of hypertension — the inhibition of the renin–angiotensin system.1 Renin, a proteolytic enzyme, is secreted by the juxtaglomerular cells of the kidney. It cleaves angiotensin I from a circulating protein substrate, angiotensinogen. Angiotensin I is in turn cleaved by another protease, converting enzyme, to form the potent pressor hormone, angiotensin II.The drug Gavras et al. tested was captopril, a converting-enzyme inhibitor that prevents the formation of angiotensin . . .
No takes yet. Share an insight, caveat, or question.
Edgar Haber (1984) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: